FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. 

Biotechnology

Pharmaceutical

FogPharma

FogPharma's headquarters in Cambridge, MA, United States

John Doherty

Olivia Sizemore

Thomas Kotarako

Marie Nguyen

Mathai Mammen

Ziyang Yu

Dave Varon

Sandra Smith

John Mcgee

Kristen Stants

Ashley Kancler

Dominic Koltenback

Kellon Asim Augustine Belfon

Wade Berry

Tucker Lynn

James Lucie

Robyn Bryce

Rebecca R. Lora

Kerry Marasa Cadigan

Steve MacDonald

Madeline Zoltek

Devon Londono

Laura Strong

Stacey Murphy Ukrainskyj

Channing Yu

Amber Wells

Jonathan Rojo

Demiana Faltaos

Lalith Akella

Madhumita Bogdan

Brian White

Elizabeth Adams Whicher

Anthony Quartararo

Lindsay J. Moore

Christie MacKenzie

Tawni Mitchell

Kaitlyn Gallitano

Krishna Yeshwant

Barbara Weber

Edward Fitzgerald

Jeffrey Leerink

David Scadden

Keith Flaherty

Fernando Camargo

Thomas Gajewski

Corey Goodman

This department conducts scientific research and develops innovative solutions in various fields.

Research and Development

This department manages and oversees all aspects of clinical research and development programs.

Clinical Development

The Research and Development Scientists at FogPharma are instrumental in driving the discovery and optimization of cell-penetrating miniproteins (CPMPs) aimed at targeting previously "undruggable" proteins involved in serious diseases. This multidisciplinary team utilizes expertise in biology, chemistry, and computational methods to explore innovative therapeutic approaches, design novel molecules, and assess their efficacy and safety through rigorous experimental studies. Their collaborative efforts are essential for translating cutting-edge scientific research into viable treatment options.

Research and Development Scientists

This department conducts research and experimentation to advance scientific knowledge in various fields.

Scientific Research

The Clinical and Translational Operations team at FogPharma is responsible for designing and executing clinical trials that evaluate the safety and efficacy of the company's innovative cell-penetrating miniproteins (CPMPs). This team collaborates closely with cross-functional partners to ensure seamless integration of translational research into clinical development, facilitating the transition of groundbreaking therapies from the lab to the clinic while addressing regulatory requirements and optimizing patient outcomes. Their efforts are crucial in advancing FogPharma's mission to target previously "undruggable" diseases.

Clinical and Translational Operations

This department oversees the management and efficiency of laboratory processes and clinical operations.

Lab Operations

FogPharma

Org chart

Board & advisors

Teams

Research and Development

Clinical Development

Research and Development Scientists

Scientific Research

Clinical and Translational Operations

Lab Operations

Offices

FogPharma

Org chart

Board & advisors

Teams

Research and Development

Clinical Development

Research and Development Scientists

Scientific Research

Clinical and Translational Operations

Lab Operations

Offices

Related companies